Tangent Reprofiling. Development of prototype: TAN2004, a safe, known drug formulated for treatment of prostate and lung cancer.

点击翻译按钮获取中文摘要

Some cancerous tumors require, or grow faster in the presence of, steroid hormones such asestrogen or testosterone. These cancers can be treated by chemotherapy drugs to prevent thetumor using hormones found naturally in the body. Many of these drugs work by blocking thereceptors for the hormone on the outside edges of the tumor, starving the tumor by preventingit from recognizing the hormone. However, many hormone-dependant tumors developresistance to these drugs by learning to make the hormones internally.We used our proprietary technology to study drugs that are currently used in non-cancerdiseases. One drug was identified as being capable of preventing internal hormone productionby tumors. This drug is already in clinical use for an alternative disease which requires longterm use, so the safety and side effects are already well characterized across a broadpopulation of patients. We propose combining this drug with a common, safe nutritionalsupplement to attack the tumor from within while maintaining the starvation proceduredescribed above.We already have data to demonstrate a reduction in growth of prostate cancer cells with thedrug in vitro, and preliminary efficacy data for prostate tumors in mice, however, we nowneed to expand this to optimise the prototype drug combination formulation and dosingschedule. We also look to expand the use into lung cancer, for which we have already seenpromising in vitro data. This project includes a first in vivo lung cancer model as well asadvanced stage prostate cancer mouse models.This project period will develop our prototype cancer treatment from proof of concept toclinic-ready, ensuring partnering for clinical development is likely on conclusion.We believe this offers an exciting opportunity to prolong successful treatment of a range ofcommon cancers including prostate and lung cancer.